Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baltimore, Maryland 21205


Purpose:

Losartan, an angiotensin receptor blocker, has been effective in preventing the development of emphysema and lung inflammation in animal models of COPD. Moreover, there is epidemiologic evidence that suggests that this drug may be effective in reducing COPD morbidity and mortality. This study will provide treatment with either losartan or placebo for a period of 12 months to determine whether there is progression of COPD as measured by high-resolution CT scans, lung function, or blood tests for inflammation.


Criteria:

Inclusion Criteria: - Evidence of COPD by pulmonary function testing Exclusion Criteria: - Clinical indication for angiotensin receptor blockers or ACE inhibitors - Significant kidney disease or heart disease - History of intolerance to losartan or similar drugs


NCT ID:

NCT00720044


Primary Contact:

Principal Investigator
Robert A Wise, M.D.
Johns Hopkins University

Marie Daniel
Phone: 410 550-0800
Email: mdaniel@jhmi.edu


Backup Contact:

Email: gleathe@jhmi.edu
Gwen Leatherman
Phone: 410 550-0800


Location Contact:

Baltimore, Maryland 21205
United States

Teresa Concordia
Phone: 410-550-2449
Email: tconcor1@jhmi.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.